GlobeNewswire by notified

Koelis Announces New Products at American Urology Association (“AUA”) Meeting

Share

GRENOBLE, France and PRINCETON, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in the care of prostate cancer, announced today the launch of new products at the prestigious American Urological Association Annual Meeting in New Orleans, LA.

Koelis will be holding live and interactive demos on its booth #1201 from May 13th to May 15th to demonstrate the exclusive technology and new features of its Trinity 3D imaging and fusion platform.

The new products include software for focal cryoablation guidance (“ProMap-FT™”); single-use transperineal biopsy grids (“Perine Grids™”); and MRI processing software (“ProMap Lite™”). Each of these new products complement the Koelis Trinity® MRI-US fusion image guidance system. The Trinity system integrates versatile 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The Koelis Trinity® system is a single, space-efficient system that does not require an interface with an external ultrasound imaging system or external electromagnetic sensors.

Mark Rooney, Koelis’ VP and General Manager in the USA, commented, “We believe that these new product launches are evidence that we are listening to our urologic customers and academic partners who are leading a paradigm shift in prostate cancer care.”

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

ProMap-FT™ expands the Koelis focal prostate ablation treatment product range to include planning and guidance software for cryoablation. With isotherm specifications on-board, the ProMap-FT software is compatible with each of the two leading vendors of cryoablation systems. Utilizing the Koelis proprietary OBT Fusion® technology, ProMap-FT also has a unique ability to safely and accurately track cryoablation needles to any targeted prostate cancer lesion. Promap-FT also offers versatility in enabling 3D guidance of laser fibers or any other interventional needle.

Single-Use Perine Grids™ includes both “full” and “mini” versions of the Company’s popular reusable transperineal needle guides. By minimizing both cross-contamination and sterilization time and labor, the Koelis single-use Perine Grids will help support the transition of transperineal prostate biopsy to an office-based procedure.

ProMap Lite™ is a software-only version of Koelis MR-Draw™ biopsy planning workstation. Designed to be compatible with PC’s and radiology workstations, ProMap Lite will add flexibility and efficiency to the workflow required to access and process a patient’s MRI prior to his fusion-guide biopsy. ProMap Lite is the first step of the Koelis strategy that ultimately will add AI and cloud-based features to the Trinity system.

Antoine Leroy, Koelis’ Co-founder and Chief Executive Officer, concludes: “Our mission is to innovate continuously to offer prostate biopsy and targeted treatment technology that advance the quality of prostate cancer care. We also seek to offer the highest level of versatility in technology choices to physicians and their patients. We are committed to support accurate and safe prostate interventions, whether these procedures are performed with or without MRI-US fusion, whether transrectal or transperineal, or whether followed-up with active surveillance or treatment.”

About Koelis: Headquartered in Grenoble, France, Koelis has been a pioneer and leader of MRI-US fusion image guidance technology for above 10 years. Featuring proprietary 3D ultrasound and prostate motion tracking software (OBT Fusion®), the Koelis Trinity® system facilitates more accurate biopsy diagnosis as well as enabling “focal” prostate cancer treatment alternatives to traditional “total” organ treatments such as surgical prostatectomy and radiation. The Company’s commitment to minimally invasive prostate cancer treatments includes a multi-center clinical registry (“Violette”, NCT04582656) in Europe based on Trinity-guided, microwave ablation technology.

Koelis: Antoine Leroy, Founder and CEO
e-mail: info@koelis.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0fff965d-28a1-41a1-8123-1be0c08f44c3

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares24.4.2024 03:36:40 CEST | Press release

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions. Goldman Sachs, Leerink Partners, Eve

UK businesses must prioritise payment technology to build customer loyalty and stay competitive: New research from Lloyds Bank and FreedomPay24.4.2024 01:01:00 CEST | Press release

London, United Kingdom, April 23, 2024 (GLOBE NEWSWIRE) -- Less than a third (27%) of businesses are confident they offer seamless payments experiences.Almost two-thirds of businesses (59%) across Retail, Food & Beverages and Hospitality believe a good checkout experience offers the same competitive advantage as having the best products.Customer preference is the factor most likely to influence businesses’ investment in payment technologies. New research from Lloyds Bank and FreedomPay highlights the importance of UK businesses investing in new payment technology. Two-thirds (59%) of UK Retail, Food & Beverage (F&B) and Hospitality companies were found to already put payments at the heart of their customer experience strategy, reflecting the growing importance of payment options to customers. For retail-focused businesses, 59% believe that a good checkout experience is essential to building customer loyalty, with respondents believing it is as much a competitive advantage as having the

Millicom announces the re-issuance of its AGM and EGM Convening Notice23.4.2024 22:30:00 CEST | Press release

Millicom announces the re-issuance of its AGM and EGM Convening Notice Luxembourg, April 23, 2024 – Millicom today announced the re-issuance of the Convening Notice to its Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) of Shareholders which will be held on May 23, 2024. The Convening Notice contains a rectified note to the AGM agenda item 20 (Share Repurchase Plan). All other items of the AGM and EGM remain unchanged. The Convening Notice is appended to this press release and available on the company’s website at: https://www.millicom.com/our-company/corporate-governance/shareholder-meetings/. AGM voting materials have been updated to reflect the rectified note. -END- For further information, please contact AGM/EGM Inquiries: Patrick Gill, Company Secretary +352 27 759 603 Maria Florencia Maiori, Senior Legal Counsel information@millicom.comPress: Sofia Corral, Director Corporate Communications press@millicom.comInvestors: Michel Morin, VP Investor Relations i

CNH announces signing of a €3.25 billion committed revolving credit facility23.4.2024 22:30:00 CEST | Press release

CNH announces signing of a €3.25 billion committed revolving credit facility Basildon, April 23, 2024 On April 19, 2024, CNH (NYSE: CNHI) signed a €3.25 billion committed revolving credit facility, intended for general corporate purposes of the Company. The facility, entered into with a group of 18 banks providing aggregate commitments in excess of €3.5 billion, has a 5-year tenor with two extension options of one year each, exercisable on the first and second anniversary of the signing date. It replaces an existing 5-year €4 billion facility due to mature in March 2026. The final size of the facility, set at €3.25 billion, aligns with reduced funding needs following the demerger of Iveco Group. The transaction confirms the strong support of a large panel of international key relationship banks for the Company. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Produc

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares23.4.2024 22:17:37 CEST | Press release

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint book-running mana

HiddenA line styled icon from Orion Icon Library.Eye